Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. by Ockenhouse, C, Sun, P, Lanar, D, Wellde, B, Hall, B, Kester, K, Stoute, J, Magill, A, Krzych, U, Farley, L, Wirtz, R, Sadoff, J, Kaslow, D, Kumar, S, Church, L, Crutcher, J, Wizel, B, Hoffman, S, Lalvani, A, Hill, A, Tine, J, Guito, K, de Taisne, C, Anders, R, Ballou, W